Antibody

383개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved383 programs
AntibodyLimited DatastaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#Melanoma+2
Trials 1Status Active
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

sequential group (Sequential treatment of bevacizumab combined with atezolizumab, Sequential treatment of bevacizumab combined with atezolizumab (sequential group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleFirst Affiliated Hospital of We…Phase 2

Serplulimab immunotherapy (Serplulimab immunotherapy)

Locally Advanced Rectal Cancer (LARC) · Locally Advanced Rectal Cancer (LARC)

#LocallyAdvancedRectalCancerLARC#Antibody#Phase2#monoclonal-antibody#First
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

same period group (Simultaneous treatment of bevacizumab combined with atezolizumab, Simultaneous treatment of bevacizumab combined with atezolizumab (same period group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleInnoventPhase 2

PD-1 inhibitor (Sintilimab, Sintilimab (PD-1 inhibitor))

Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#LargeBCellDiffuseLymphoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleInnoventPhase 2

Sintilimab and Bevacizumab Combined with Radiotherapy (Sintilimab and Bevacizumab Combined with Radiotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Innovent
Trials 1Status Active
AntibodyLimited DatastaleInnoventPreclinical

Sintilimab combined with Bevacizumab (Sintilimab combined with Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Preclinical#monoclonal-antibody#Innovent
Trials 1Status Active
AntibodyLimited DatastaleMoonLake Immunotherapeutics AGPhase 2

Sonelokimab (Sonelokimab)

Arthritis, Psoriatic · Arthritis, Psoriatic

#ArthritisPsoriatic#Antibody#Phase2#monoclonal-antibody#Arthritis+2
Trials 1Status Active
AntibodyLimited DatastaleMoonLake Immunotherapeutics AGPhase 2

M1095 (Sonelokimab, Sonelokimab (M1095))

Hidradenitis Suppurativa · Hidradenitis Suppurativa

#HidradenitisSuppurativa#Antibody#Phase2#monoclonal-antibody#MoonLake
Trials 1Status Active
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 2

Standard Dose Bevacizumab (Standard Dose Bevacizumab)

Brain Cancer; Glioblastoma · Brain Cancer

#BrainCancer#Antibody#Phase2#monoclonal-antibody#Glioblastoma+1
Trials 1Status Active
AntibodyLimited DatastaleOslo University HospitalPhase 3

daratumumab (Darzalex, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#Oslo
Trials 1Status Recruiting
AntibodyLimited DatastaleRocheApproved

Subconjunctival Bevacizumab (Subconjunctival Bevacizumab)

Glaucoma · Glaucoma

#Glaucoma#Antibody#Approved#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePreclinical

Altuzan (Subconjunctival bevacizumab, Subconjunctival bevacizumab (Altuzan))

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 1

Superselective Intraarterial Cerebral Infusion of Cetuximab (Superselective Intraarterial Cerebral Infusion of Cetuximab)

Glioblastoma Multiforme (GBM); ANAPLASTIC ASTROCYTOMA (AOA) · Glioblastoma Multiforme (GBM)

#GlioblastomaMultiformeGBM#Antibody#Phase1#monoclonal-antibody#ANAPLASTICASTROCYTOMAAOA+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 1

TACE combined with sintilimab and bevacizumab (TACE combined with sintilimab and bevacizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleSecond Affiliated Hospital of G…Phase 2

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase2#monoclonal-antibody#Second
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

atezolizumab (Tecentriq, TACE-HACI, plus atezolizumab-bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Sun
Trials 1Status Recruiting
AntibodyLimited DatastaleDaping Hospital and the Researc…Phase 2

TP + Cetuximab + Tislelizumab (TP + Cetuximab + Tislelizumab)

LA HNSCC · LA HNSCC

#LAHNSCC#Antibody#Phase2#monoclonal-antibody#Daping
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

trastuzumab (TX05, TX05 (trastuzumab))

Breast Cancer; Breast Neoplasms · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#BreastCancer+2
Trials 1Status Active
AntibodyLimited DatastaleJanssen Research & Development,…Phase 2

Talacotuzumab (Talacotuzumab)

Myelodysplastic Syndromes · Myelodysplastic Syndromes

#MyelodysplasticSyndromes#Antibody#Phase2#monoclonal-antibody#Janssen
Trials 1Status Active

16 / 20 pages

← PreviousNext →